MICRUS ENDOVASCULAR CORP
SymbolMEND

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

Micrus Endovascular Reports Fiscal Second Quarter Revenues of $21.5 Million and Diluted EPS of $0.22

2009-11-05 04:00 ET - News Release

Increases Fiscal 2010 Revenue Guidance


SAN JOSE, Calif. -- (Business Wire)

Micrus Endovascular Corporation (Nasdaq: MEND) today reported financial results for the three and six months ended September 30, 2009 and increased fiscal 2010 revenue guidance.

Highlights for the second quarter and first six months of fiscal 2010 include the following (comparisons are with the comparable periods in fiscal 2009):

  • Neurovascular revenues from the United States increased 15% to a record $11.2 million in the second quarter, and increased 16% to $21.3 million in the first six months
  • Revenues from Europe increased 5% (or 8% in constant currencies) to $6.4 million in the second quarter, and increased 9% (or 18% in constant currencies) to $12.7 million in the first six months
  • Revenues from Asia Pacific decreased $0.5 million to $2.8 million in the second quarter, and increased 18% to $6.5 million in the first six months
  • Total revenues increased 3% (or 4% in constant currencies) to $21.5 million in the second quarter, and increased to 9% (or 12% in constant currencies) to $42.7 million in the first six months
  • Operating income increased $4.1 million to $2.1 million in the second quarter compared with an operating loss of $2.0 million in the prior-year period; operating income for the six months increased $13.0 million to $4.1 million versus an operating loss of $8.9 million in the prior-year period
  • Total cash as of September 30, 2009 of $24.3 million increased $7.2 million from March 31, 2009

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.